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Background: Positioning a patient lying-flat in the acute phase of ischaemic stroke may improve recovery and reduce
disability, but such a possibility has not been formally tested in a randomised trial. We therefore initiated the
Head Position in Stroke Trial (HeadPoST) to determine the effects of lying-flat (0°) compared with sitting-up
(≥30°) head positioning in the first 24 hours of hospital admission for patients with acute stroke.
Methods/Design: We plan to conduct an international, cluster randomised, crossover, open, blinded outcome-
assessed clinical trial involving 140 study hospitals (clusters) with established acute stroke care programs. Each
hospital will be randomly assigned to sequential policies of lying-flat (0°) or sitting-up (≥30°) head position as a
‘business as usual’ stroke care policy during the first 24 hours of admittance. Each hospital is required to recruit
60 consecutive patients with acute ischaemic stroke (AIS), and all patients with acute intracerebral haemorrhage
(ICH) (an estimated average of 10), in the first randomised head position policy before crossing over to the second
head position policy with a similar recruitment target. After collection of in-hospital clinical and management data and
7-day outcomes, central trained blinded assessors will conduct a telephone disability assessment with the modified
Rankin Scale at 90 days. The primary outcome for analysis is a shift (defined as improvement) in death or disability
on this scale. For a cluster size of 60 patients with AIS per intervention and with various assumptions including an
intracluster correlation coefficient of 0.03, a sample size of 16,800 patients at 140 centres will provide 90 % power
(α 0.05) to detect at least a 16 % relative improvement (shift) in an ordinal logistic regression analysis of the primary
outcome. The treatment effect will also be assessed in all patients with ICH who are recruited during each treatment
study period.
Discussion: HeadPoST is a large international clinical trial in which we will rigorously evaluate the effects of different
head positioning in patients with acute stroke.
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Stroke is a major global disease burden for which there
are few proven treatment options. Acute ischaemic stroke
(AIS) is the most frequent pathological subtype [1],
where the likelihood of a patient’s having died or being
dependent at 6 months is greater than 50 % [2]. In this
disease, an occluded artery by in situ thrombus or embol-
ism from a more proximal source (i.e., cardiac or extracra-
nial vessels) impedes cerebral blood flow (CBF). The size
and site of such an occlusion, as well as the efficiency of
compensatory collateral blood flow, determine the extent
of at risk (‘ischaemic penumbra’) and dead (‘infarcted’)
brain [3]. As autoregulation is lost in the affected area,
local CBF is considered to depend passively on mean
systemic arterial blood pressure [4].
A simple way of potentially increasing CBF via the
collateral circulation and into the ischaemic penumbra
is to put the patient with AIS into a lying-flat (0°) head
position. Several observational studies have used trans-
cranial Doppler (TCD) to show that the lying-flat position
is associated with an increase in CBF velocities within
major cerebral arteries [5, 6]. Moreover, a significant in-
crease in TCD-recorded mean flow velocity, and thus
presumed CBF, has been recorded in the stroke-affected
hemisphere, but not on the contralateral side, of patients
with AIS who were positioned lying-flat (at 0° or 15°) com-
pared with those positioned sitting-up (≥30°) [7]. However,
the relevance of these changes to any improvement in
clinical outcomes after AIS is uncertain at this time [8, 9].
In the subset of patients with mass effect caused by cere-
bral oedema in acute stroke, such as those with malignant
middle cerebral artery infarction or primary intracerebral
haemorrhage (ICH), sitting-up may improve the chances
of a good outcome. Extrapolating from patients with acute
brain injury, the authors of a systematic review of head
positioning showed that intracranial pressure is decreased
significantly when the head is elevated from 0° to 30°,
whereas cerebral perfusion pressure is generally unchanged
[10]. However, there appears to be little or no change in
cerebral perfusion pressure reported in patients with differ-
ent types of acute stroke [11, 12].
A common concern among clinicians is that position-
ing a patient lying-flat may increase the risk of aspiration
pneumonia. The risk of pneumonia by aspiration of
gastric contents is increased in the presence of dysphagia
[13, 14] and where mechanical ventilation is required [15],
but it is only in mechanically ventilated patients that the
risk of pneumonia appears higher while they are lying-flat
compared with sitting-up [16]. Although some clinical
guidelines recommend that patients with stroke should
be nursed with their head elevated to reduce the risk of
aspiration pneumonia [17], the conclusion of a recent
study was that avoidance of the lying-flat position over
concerns of pneumonia may be unjustified, as the authorsfound a very low frequency (4.5-6 %) of pneumonia caused
by lying-flat in patients with AIS after thrombolysis [18].
There is currently no clear evidence regarding the risks of
aspiration pneumonia related to different head positions
in nonventilated patients with acute stroke. Furthermore,
side-lying and avoidance of feeding in these patients are
likely to reduce such risks [19, 20].
Another argument against laying patients flat in bed is
that it may delay mobilisation and rehabilitation. Even
though a pilot phase study suggested that very early (<24
hours) rehabilitation was safe and associated with a non-
significant improvement in function [21, 22], the main
results of the pivotal A Very Early Rehabilitation Trial for
Stroke (AVERT) showed that a high-dose very early mo-
bilisation protocol that included frequent out-of-bed sit-
ting, standing and walking activity was associated with
a reduction in the odds of a favourable outcome at 3
months compared with usual care [23]. To date, there is
no evidence to support intense very early mobilisation in
the first 24 hours after the onset of acute stroke.
Regarding physiological parameters, although most
patients do not experience clinically significant desatur-
ation when their body position is changed, side-lying
may reduce arterial oxygen saturation, particularly in pa-
tients with severe stroke associated with right hemiparesis
and concomitant chest disease [24]. Moreover, stroke pa-
tients who are nursed in a sitting position may have higher
arterial oxygen saturation levels than those in a supine
position [24, 25]. Nevertheless, the results of the AVERT
trial [23] suggest that increasing periods of sitting-up in
the early phase of acute stroke may not necessarily im-
prove outcome. The influence of changes in arterial oxy-
gen saturation related to position on brain recovery and
outcome after acute stroke remains to be confirmed.
We initiated the Head Position in Stroke Trial (Head-
PoST) to determine the balance of risks and benefits
associated with the lying-flat versus sitting-up head
position in patients with acute stroke without a definite
indication or contraindication to either intervention ap-
plied within the first 24 hours of admission to hospital.
A cluster randomised design with the interventions under
investigation applied as part of usual background nursing
care was chosen to avoid contamination and maximise ad-
herence, reliability and generalisability of the results. A
crossover component is added to provide all hospital sites
with a standardised change of policy, which will allow us
to control for confounding factors that may be associated
with differences in the organisation and levels of back-
ground care across hospitals.
Aims
The primary aim of HeadPoST is to compare the effects
of lying-flat (0°) with sitting-up (≥30°) in the first 24
hours of admission for patients presenting with AIS on
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Rankin Scale (mRS) score [26] at 90 days. This outcome
pertains to the individual participant level.
The key secondary aims are to determine whether
lying-flat (0°) is superior to sitting-up (≥30°) with regard
to poor outcome (death and neurological impairment
based on the National Institutes of Health Stroke Scale
[NIHSS] [27]) at 7 days in patients with AIS, whether
sitting-up (≥30°) is superior to lying-flat (0°) on early
(death and neurological impairment at 7 days) and late
outcomes (according to mRS scores at 90 days) and early
neurological recovery (NIHSS at 7 days) in acute ICH,
the effects of the two head positions on overall and cause-
specific death separately by 7 and 90 days, serious adverse
events (SAEs) and length of hospital stay.
Methods/Design
Trial design
HeadPoST is an international, multicentre, prospective,
cluster randomised, crossover, blinded outcome-assessed
trial to be conducted through a global network of inves-
tigators, with hospitals as the unit of randomisation
(clusters). All hospitals will participate in both the lying-
flat (0°) and the sitting-up (≥30°) head position treatment
phases. They will enrol and implement the intervention
until the target number of patients is reached before cross-
ing over to the opposite intervention. The study scheme
outlines the flow and crossover of interventions (Fig. 1).Fig. 1 Trial schemaTrial population
The trial will be conducted in approximately 140 hospi-
tals (sites) in Australia, Brazil, Chile, China, Mongolia,
Singapore, Taiwan and the United Kingdom in the first
instance. Hospitals in other countries will be invited to
join according to interest, feasibility and resources. Sites
are required to fulfil certain eligibility criteria, including
having an established acute stroke care program within a
geographically defined area for the management of stroke
patients (i.e., an acute stroke unit [ASU]) and a sufficient
projected throughput of patients to ensure feasibility of re-
cruitment within a short time frame.
Consent process and participant inclusion and exclusion
criteria
Each participating site must obtain written approval from
its research ethics committee (REC) (e.g., institutional re-
view board [IRB]), as well as from any other relevant re-
gional or national bodies, before patient recruitment can
commence. A list of all ethical bodies that have approved
the study is provided in Additional file 1. A mixed consent
process is proposed, according to local and/or national
rules and regulations, as outlined in Table 1. Consent
under the cluster guardian format or appropriate approval
is necessary to prevent contamination of the intervention
across patients nursed in closed proximity and by busy cli-
nicians caring for multiple patients [28]. It is also likely to
avoid responder bias in patients (or their surrogates) as a
Table 1 Consent options for the HeadPoST trial
Hierarchy of consent options proposed in this study
1. Cluster guardian consent or appropriate approval (e.g., signed by
general manager or chief executive of hospital or by head of
neurology/stroke department) for the randomised head position to
be the usual nursing care for patients with acute stroke, obtained
before commencement of the study
With any of the following:
2. a. Recommended: Opt-out consent obtained from patients for the
collection of data through in-person assessment and extraction of
information from medical records during the hospital stay and
follow-up, and release of personal information to allow centralised
follow-up at 90 days after initial admission to the hospital for
research purposes
b. Alternative: Individual patient consent for collection of in-hospital
data and for release of personalised information for research purposes
to allow centralised follow-up at 90 days after the initial admission to
the hospital
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standard care [29]. Under the guardian consent process,
all eligible patients will receive the intervention as stand-
ard of care and will be provided with an approved Patient
Information Sheet (PIS) and Consent Form as soon as
practical after admission. According to the local REC-
approved consent process, patients’ written consent to be
either included or excluded—opt-in or opt-out patient
consent, respectively—will be obtained before enrolment
to collect their medical and personal information and
to contact them again for follow-up at 90 days. These
patients will also be able to formally opt out at any stage
of the study.
The patient eligibility criteria have been kept simple to
facilitate the implementation of the randomised head
position as a standard of care and for evaluation of the
treatment effect in a broad range of patients. Consecutive
eligible patients with acute stroke will be approached to
participate in the trial. The patient inclusion and exclusion
criteria are given below.
Inclusion criteria
All patients are eligible for the allocated intervention if,
at the time of presentation to the hospital, they meet
each of the following criteria:
1. Adult aged 18 years or older (a younger age of 16
years may be used in some countries)
2. Presumed clinical diagnosis of acute stroke (i.e., with
a persistent neurological deficit on presentation)
3. Either present directly, are transferred from another
hospital or have had an in-hospital event
Exclusion criteria
Patients are to be excluded from the allocated interven-
tion if at the time of presentation they meet any of the
following criteria:1. A resolved transient ischemic attack (i.e., brief
neurological symptoms that are judged to have
completely resolved upon presentation)
2. A definite clinical contraindication or indication for
either the sitting-up or lying-flat head position
3. A significant medical condition that takes priority in
care and where adherence to the randomised head
position is not possible on another ward or department
of the hospital, such as for haemodialysis or surgery
(e.g., carotid endarterectomy, haematoma evacuation)
4. Not consenting to participate in HeadPoST
5. Previously enrolled in HeadPoST
Randomisation
The unit of randomisation is the hospital. A statistician
not otherwise involved in the trial will generate the rando-
mised allocation sequence and treatment group assign-
ment of either lying-flat (0°) or sitting-up (≥30°) as the
first intervention before crossover to the other inter-
vention. Participating sites will be stratified according
to country, and the allocation sequence will be concealed
until the interventions are assigned.
Interventions
The allocated interventional head position is to be applied
to all consecutive presenting (or in-hospital) eligible pa-
tients as soon as possible after the clinical diagnosis of
stroke is made. This pertains to both the cluster and
patient levels.
Lying-flat (0°)
Patients will be positioned lying-flat (0°) as soon as pos-
sible after presentation to the emergency department
(ED) or other assessment area, unless there is a specific
contraindication. Patients are to remain in this position
for at least 24 hours. Patients can have a swallow screen
and/or swallow assessment and can be allocated nil-by-
mouth (NBM), nasogastric feeding, modified diet or normal
diet, according to local protocols. However, it is recom-
mended that nasogastric feeding be undertaken only as
bolus feeds (i.e., not continuous) and with the patient in a
sitting position for short periods as necessary to reduce the
risk of aspiration [19]. All other feeding can be undertaken
with the patient lying down, unless this position is definitely
not tolerated, in which case the patient can sit up for no
more than 30 minutes. It is possible for patients to eat on
their side in the flat position, as swallowing is an active
process that is not dependent on gravity. Patients should
have no more than three breaks of 30 minutes from a
flat position in the first 24 hours, and breaks should
not to be grouped together (i.e., no back-to back breaks
are permitted). All patients should be toileted in bed or
in a commode near the bed, where possible. Gentle graded
mobilisation with toilet privileges, and elevation of the
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be raised gradually after 24 hours of lying-flat, if neces-
sary, but patients with moderate to severe neurological
deficits may have the flat position maintained for lon-
ger. Patients are to be mobilised according to local stroke
care guidelines.
Sitting-up (≥30°)
Patients will be positioned sitting-up with head elevated
at least 30° by raising the head of the bed or using extra
pillows, whichever is more appropriate, immediately upon
presentation to the ED, and they are to remain in this
position for at least 24 hours. Patients can have a swallow
screen and/or swallow assessment and can be allocated
NBM, nasogastric feeding, modified diet or normal diet,
according to local protocols. In the unlikely situation that
a patient has to be nursed with the head lowered (e.g., to
perform computed tomography), the same time-off re-
strictions are applied (i.e., no more than three breaks of 30
minutes in a lying-flat (0° or <30°) position in the first 24
hours and no break periods to be grouped together). Feed-
ing may commence after patients have passed an appro-
priate swallowing screening test or swallowing assessment.
Those patients will be allowed mobilisation according to
local guidelines.
Background care
All patients with acute stroke should be managed by a
dedicated team in an ASU (or high-dependency unit or
intensive care unit) during the period of the intervention.
Their management should be best practice standard of
care according to regional guidelines, including use of a
swallowing screen or swallowing assessment before any
feeding is initiated.
Trial outcomes
Trial outcomes pertain to patient-level data. The overall
primary outcome of HeadPoST is a shift (improvement)
in death and disability according to an independent tele-
phone assessment using the mRS [30] at 90 days. The
secondary outcomes are death or dependency measured
by a shift in NIHSS [27] at 7 days, death within 90 days,
length of hospital stay, health-related quality of life ac-
cording to the 5-dimension European Quality of Life Scale
(known more commonly as the EQ-5D) and pneumonia
according to standard criteria involving a set combination
of symptomatology and radiological signs [31].
Data collection and follow-up
Sites should record details of all patients admitted with
acute stroke, and all patients should be placed in the
randomised head position unless there is a clear contra-
indication (e.g., cardiac or respiratory failure). All patients
will be approached for enrolment for data collectionwithin the trial by site study coordinators and investi-
gators. Brief demographic details of all stroke patients
who are approached but who are not enrolled, and the
reason for nonenrolment, will be recorded on a screen-
ing and enrolment log to determine selection bias. For
safety analysis, sites are requested to provide information
on any death known among registered nonenrolled pa-
tients during follow-up. To assist the implementation of
the intervention at each site, information will be gathered
on the organisational structure of the site and the various
clinical wards that will be involved in the intervention.
Each site’s lead investigator is required to complete a hos-
pital organisation questionnaire, developed based upon
previous surveys in this field [32–34], to assist the regional
coordinating centre (RCC) in preparing the training and
site initiation visit (see Additional file 2).
The goal of the main assessments of participants in
the first 24 hours will be to promote adherence to the al-
located head position. A monitoring chart will be main-
tained by clinical staff to record the duration in the allocated
head position, but importantly also the time spent out of
position with a description of the reason. Basic physiological
parameters will also be recorded. Sites are also required to
collect a limited amount of data on patients at the time
of admission (day 1) and separation (day 7 or at discharge,
transfer or death, if earlier), as well as all SAEs, including
death, until 90 days.
Appropriately trained outcome assessors, who are kept
blind to the management of patients, will use a script to
conduct a telephone assessment of health and function-
ing at 90 days.Serious adverse events
The SAEs are defined as recommended by the World
Health Organisation International Drug Monitoring Centre.
The mechanisms for reporting and notifying SAEs are
based on the guidelines adopted by the International Con-
ference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use – Good
Clinical Practice (ICH-GCP) [35] and refer to those related
to each patient recruited into the study from the period of
enrolment until the assessment at 90 days. The inter-
national coordinating centre (InCC) will closely monitor all
SAEs for any relationship to the study procedures and
protocol and for any clustering of events at a particular site.
The protocol will be amended or the trial stopped early if
an excess of a particular SAE appears to be protocol-
related, including pneumonia, neurological deterioration
and heart failure. In addition, the InCC will submit all
SAEs to the appointed independent Data and Safety
Monitoring Board (DSMB) for regular review and, if
needed, outside the planned safety and interim analysis
meetings.
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RCCs will be set up in the various countries to facilitate
the compliance and translation of the protocol to meet
local regulations. RCC staff will receive training and as-
sistance from the InCC in the setup and documentation
required for the study in accordance with the Declaration
of Helsinki and ICH-GCP standards. There will be regular
meetings and/or teleconferences between the RCC and
InCC staff. The InCC will provide standard operating pro-
cedures (SOP) to the RCCs and sites to assist with compli-
ance with the protocol. Manuals and guidelines will be
developed by the InCC in liaison with the operations
committee. Training will be provided in both online and
face-to-face meetings undertaken by staff from the RCCs
using the training materials developed specifically for the
study.Monitoring of sites
RCC-based clinical research monitors will perform online
and on-site data verification and monitor the conduct of
the study. A nominated ‘local champion’ at each site will
assist in assessing compliance with the head position by
providing ongoing training, solutions to local barriers and
ad hoc checking of the positioning procedure and record-
ings in the ED, the ASU ward, and any relevant wards that
take stroke patients in the first 24 hours. In addition,
experienced RCC research staff will undertake quality
control activities necessary for conduct of the trial.
Monitoring serves to confirm adherence to the protocol
and guidelines, relevant local and regional ethical require-
ments, and data accuracy and quality.Coenrolment
As the HeadPoST trial is a cluster randomised controlled
trial of an organizational change, there are no methodo-
logical contraindications to coenrolment of patients into
individual patient randomised controlled trials. Although
the aim is to recruit all consecutive stroke patients, allow-
ance is made for coenrolment of patients into individual
patients’ randomised pharmaceutical investigational or
rehabilitation trials, or into observational registry studies,
provided that this is acceptable to participants (who will
likely have to complete additional follow-up requirements),
the local REC, cluster guardians and competing trial spon-
sors/chief investigators. As most conventional individual
patient randomised clinical trials recruit only a minority
(e.g., 2-10 %) of all patients, it is anticipated that only a
few patients could be enrolled in multiple research studies
or clinical trials. If coenrolment is unacceptable and pa-
tients are included in another trial, then an explanation is
to be given in the screening log regarding why selected pa-
tients were excluded from HeadPoST.Statistical considerations
Sample size
In patients with AIS, lowering the head from 30° to 15°
or 0° has been associated with up to 12 cm/s increases
in mean CBF in the middle cerebral artery on TCD [12,
36–38]. Other studies have shown that a 1 cm/s increase
in CBF is associated with a 0.7-point reduction in NIHSS
score [9] and a 16 % reduction in death or dependency
based on the mRS [39], whereas the score distributionin
the sitting-up head position has been reported to be 0
(18 %), 1 (18 %), 2 (16 %), 3 (15 %), 4 (12 %), 5 (12 %)
and 6 (death, 9 %) [40]. For a cluster size of 60 patients
with AIS for each intervention (i.e., lying-flat or sitting-
up), and assuming 5 % crossover and 10 % dropout rates
in each hospital, recruitment failure in 10-15 % of hospi-
tals, and an intracluster correlation coefficient of 0.03
(conservatively estimated from an intracluster correl-
ation coefficient of 0.018 in another cluster controlled
trial [41] undertaken across 19 ASUs in New South Wales,
Australia), a sample size of 16,800 patients with AIS at 140
sites will provide 90 % power (α 0.05) to detect at least 16 %
improvement (shift) in death and disability on the mRS at
day 90 in the ordinal logistic regression analysis [42, 43].
There will also be 90 % power to detect at least 16 % im-
provement (shift) in neurological function on the NIHSS at
day 7, at least 30 % reduction in death and at least a 2-day
reduction in length of stay for such patients.
For patients with acute ICH, the cluster size will be
smaller and may vary across sites (10-30 %), particularly
between China and elsewhere [1, 44], depending on the
frequency of ICH. Assuming a recruitment of 10 ICH
patients on average per site for each intervention period,
a sample size of 2,800 patients with ICH at 140 sites will
provide 90 % power (α 0.05) to detect at least 25 % im-
provement (shift) in death or disability associated with
the sitting-up head position. Moreover, there will be 90 %
power to detect at least 25 % improvement in NIHSS at
day 7, at least 33 % decrease in death and at least a 2-day
reduction in length of stay for these patients.
The power of the trial is derived from having a very
large number of clusters, which we consider achievable
because the workload at each site will be kept low and
for a short period of time. The inflation of the cluster
size and the number of clusters are being done to take
account of stroke mimics, poor recruitment and quality
issues. An overall target of 70 patients in each interven-
tion group is derived from the requirement of 60 and 10
with AIS and ICH, respectively. For the smaller ASUs
with fewer than 200 people admitted with stroke per
annum, the sample size will likely be achieved over 4
to 5 months, so, taking account of the crossover and
90-day follow-up, the total duration of the study is ap-
proximately 12 months. For large ASUs, and especially for
the hospitals in China with over 1,200 stroke admissions
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tients to be recruited is likely achieved just over several
weeks, for a study duration of 4 to 5 months.Data analysis
We will analyse patients in the treatment group to which
they are allocated according to the intention-to-treat
principle. We will compare patients allocated to lying-flat
with those allocated to sitting-up. The primary analysis
will be unadjusted, but adjusted analyses can also be
carried out on the primary and secondary outcomes if
required. All analyses will be adjusted for clustering
within sites. No adjustment for multiplicity is planned,
as there are only a small number of prespecified effi-
cacy outcomes being investigated. All analyses will be
undertaken at the patient level on an intention-to-treat
basis, as defined by allocated head position at each hos-
pital, using generalised estimating equations (GEE) or
random-effects regression to account for clustering.
The primary outcome of death or disability according
to the mRS [26] score at 90 days will be analysed by
means of GEE for ordinal data (i.e., the natural extension
of ordinal logistic regression [‘shift’] analysis for clustered
data), in which mRS as a dependent variable with seven
levels (ranging from 0 [no residual symptoms] to 6
[death]). The secondary outcome of the NIHSS [27]
score at 7 days will also be analysed similarly, as the
NIHSS [27] is considered as an ordinal endpoint with
seven levels [45]. Binary secondary outcomes will be
analysed by means of standard GEEs with a logistic link
and/or time-to-event type endpoints using the Cox
model with a sandwich formula [46]. For continuous
outcomes, a random intercept linear regression model
will be used. Descriptive statistics will be provided for
safety data. The number of patients reporting any SAEs
and the occurrence of specific SAEs will be tabulated.
Tests of a treatment effect on specific SAEs may be
attempted by means of a χ2 test adjusted for clustering.
Subgroup analyses will also be conducted to investigate
the effects of the interventions in different pathological
subtypes of AIS, defined as small vessel ‘lacunar’, large
vessel, cardioembolic and other.Process evaluation
By exploring the way in which each of the study interven-
tions is implemented, it will be possible to provide insights
into why each was successful and how each one can be
optimized, and the reasons for the failure of an inter-
vention or for unexpected consequences can be analysed
[47–49]. Furthermore, assessment of implementation is
essential for analysing the internal and external validity of
interventions [49].Among a set of key implementation measurements
identified [50], those most relevant to HeadPoST include
assessment of the following:
1. Fidelity: By monitoring the positioning policy that
sites are implementing
2. Dosage: By assessing for how many periods and for
how long patients have been in a particular head
position during the first 24 hours
3. Quality of intervention delivered: By monitoring the
delay until the start of the intervention after admission
4. Program reach: Percentage of eligible population
who participated, derived from data on enrolment
and screening logs
5. Adaptations to program during implementation: By
recording feedback from investigators
In addition, semistructured interviews with selected
health care providers will be conducted by local research
staff during the site initiation process to assess any po-
tential barriers and their solutions for delivering the
implementation, as barrier assessment is proven to pro-
mote clinician behaviour change [51]. Such data will
potentially optimise the implementation process during
the trial, as well as inform strategies for the potential
rollout of the intervention after the trial.Data management
The internet-based data management system will be man-
aged at the InCC, which has extensive experience in clin-
ical trial data capture and security. The InCC has in place
system security SOP with VeriSign SSL digital certification
and an encrypted HTTPS connection (IT-SOP-105 v1.4).
Registration and data entry will be performed at the
participating sites via the password-protected, encrypted
HTTPS connection. Only staff listed in the delegation log
will be given unique individual passwords to access the
internet-based data management system. This system has
been developed at the InCC for data capture. The data
variables will have logic checks within the acceptable
ranges and mandatory fields to ensure accuracy and re-
duce missing data. Reports and data query management
will also be included in the system to assist with centra-
lised online monitoring by the InCC and the RCC.
Paper case report forms will be provided for sites pre-
ferring to use these for the initial collection of data. These
forms will be used as source documents and will need to
be signed and dated by the investigator completing the
form. All computerised forms will be electronically signed
(by use of the unique password) by the authorized study
staff, and all changes made following the initial entry will
have an electronic dated audit trail. It is required that the
collection of data and transfer of information for the
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local IRB at each site.
Confidentiality and privacy
Every precaution will be taken to respect the privacy of
patients in the conduct of the study. To maintain patient
confidentiality, only deidentified data will be used for
statistical analyses and publication of results. However,
as part of the centralised follow-up service, the InCC
at The George Institute for Global Health (Sydney,
Australia) and the RCCs will use contact sources recorded
by the sites to undertake the 90-day assessment. Only
names, telephone numbers, next of kin and contact details
of a patient’s general practitioner will be sent to the RCC
to undertake the follow-up assessment. The information
will be encrypted and password-protected before being
sent by email in batches. This information will be included
in the PIS. In the course of monitoring data quality and
adherence to the study protocol, the monitor will refer to
medical records at the participating hospital. This infor-
mation will be included in the PIS. All individual and site
information will be deidentified in reporting data and re-
sults to protect the confidentiality of participants.
Discussion
If positioning the patient in the acute phase of stroke
has a significant beneficial effect on outcome, there is po-
tential to have a major public health impact for a widely
generalisable, affordable health care intervention. In the
setting of AIS, the principal therapeutic approach is to re-
store antegrade perfusion within the ischaemic territory
through early use of recombinant tissue plasminogen acti-
vator or a mechanical endovascular treatment, but both
approaches are limited by access barriers and potential
harms. Another potential therapeutic approach is to aug-
ment cerebral perfusion through three anatomical systems
in the brain: large artery communications between the
intra- and extracranial circulation, the circle of Willis, and
leptomeningeal anastomotic channels [52]. The extent of
leptomeningeal collateral vessels, as visualised by com-
puted tomography with angiography, has been shown to
be associated with outcome in AIS [53], and the presence
of good collateral circulation determined by conventional
cerebral angiography indicates a good prognosis after
endovascular treatment for AIS [54]. Although increasing
industry attention is being focused on the use of partial
aortic occlusion pumps or external counterpulsation to in-
crease CBF [55, 56], a far simpler approach to enhancing
the cerebral collateral circulation is through lying patients
flat in the hyperacute phase of AIS.
Although sitting patients up is standard policy for
patients with acute stroke in most Western countries,
an increasing number of ‘early adopter’ stroke centres
(e.g., Switzerland) have introduced the lying-flat positionfor patients with AIS, in either all or specific subtypes of
patients (i.e., occlusion of large proximal cerebral vessels)
on the basis of encouraging data derived from small ob-
servational studies demonstrating increased CBF on TCD.
Conversely, in low-income settings and/or countries,
where most of the global stroke burden exists, the lying-
flat position is widely applied because of the use of simple,
nonmechanical beds. Taken together with other geographic
variations in nursing practices and hospital care policies,
the manner in which patients with acute stroke are nursed
could be critical to rates of pneumonia.
In the absence of randomised trial evidence, there will
be ongoing variation in opinion and policy over the most
appropriate patient position in the acute phase of both
the AIS and ICH forms of acute stroke. Such a low-cost
and widely applicable policy regarding the position of the
patient—lying-flat versus sitting-up—has potential for
having a significant health impact in this major disease.
HeadPoST has been designed to determine the efficacy
and safety of a simple nursing intervention in patients
with acute stroke. The trial uses broad inclusion criteria
and will be conducted across different health care set-
tings to support the generalisability of results. The study
aims to provide reliable evidence on the optimal head
position to inform policy in the management of patients
in the initial 24 hours following acute stroke.
Administrative information
Steering committee
The study will be overseen by an international steering
committee (SC) comprised of experts in the fields of
stroke, neurocritical care, neurology, geriatrics, cardiovas-
cular epidemiology and clinical trials. The SC will consist
of regional country leaders and grantholders.
The following are the SC members: Professor Gillian
Mead (Chair), University of Edinburgh, UK; Professor
Craig Anderson (Deputy Chair and Principal Investigator),
University of Sydney, Australia; Associate Professor Maree
Hackett (Chief Investigator), University of Sydney, Australia,
and University of Central Lancashire, Preston, UK; Associate
Professor Laurent Billot, University of Sydney, Australia;
Professor Hisatomi Arima (Chief Investigator), University of
Sydney, Australia, and Shiga University of Medical Sciences,
Otsu, Japan; Professor Pablo Lavados and Dr Verónica
Olavarría, Clínica Alemana de Santiago, Universidad del
Desarrollo, Santiago, Chile; Professor Sandy Middleton,
Australian Catholic University and St Vincent’s Health
Australia, Sydney, Australia; Professor Caroline Watkins,
University of Central Lancashire, Preston, UK; Professor
Thompson Robinson, University of Leicester, UK; Professor
Liying Cui and Professor Bin Peng, Peking Union Medical
College Hospital, Beijing, China; Professor Octavio
Pontes-Neto, University of Sao Paulo, Brazil; Dr
Lkhamtsoo Natsagdorj, Stroke Unit, State Third Hospital,
Muñoz-Venturelli et al. Trials  (2015) 16:256 Page 9 of 11Ulanbaatar, Mongolia; Professor Ruey-Tay Lin, Stroke
Centre, Kaohsiung Medical University Chung-Ho Memorial
Hospital, Kaohsiung Taiwan; and Professor Tsong-Hai
Lee, Linkou Chang Gung Memorial Hospital, Taoyuan,
Taiwan.
Responsibilities of the steering committee
The SC will have overall responsibility for the execution
of the study protocol, data collection and analysis plan,
and publications. The SC has the right to appoint new
members and coopt others to add to the integrity of the
conduct of the study and analyses.
Advisory committee
The following are the members of the advisory committee:
Associate Professor Stephane Heritier, Monash University,
Melbourne, Australia; Dr Emma Heeley, University of
Sydney, Australia; Professor Richard Lindley, University
of Sydney, Australia; Associate Professor Stephan Jan,
University of Sydney, Australia; Professor Mark Woodward,
University of Sydney, Australia; Elizabeth Boaden, University
of Central Lancashire, Preston, UK; Dr Alejandro Brunser,
Clínica Alemana de Santiago, Universidad del Desarrollo,
Santiago, Chile.
Coordinating centres
Central international coordination will be handled at The
George Institute for Global Health, Sydney, Australia, and
together with RCCs established and located in Beijing,
China; Preston, UK; and Santiago Chile.
International coordinating centre
The InCC is supported by key grantholders and project
staff. It is responsible for day-to day management of the
study, data and project management, committee coordin-
ation, assistance with ethics committee applications, proto-
col and procedures for training of participating sites,
overseeing of initiation visits and activation of partici-
pating sites, monitoring of data quality and adherence
to protocol, adherence to applicable guidelines and reg-
ulations, and preparation of study data for analysis and
publication.
Regional coordinating centres
The RCCs are established in China, the United Kingdom
and South America with responsibilities for providing
advice to the InCC on regional issues relevant to the setup,
translation and management of the study. In addition,
working with the InCC, they will provide assistance and
support in obtaining REC approvals; training and activating
sites; and monitoring study progress at participating sites
in their region, including data quality and adherence to the
study protocol. The RCCs also will assist in identifying andoverseeing the centralised follow-up assessment process
for their regions.Data and Safety Monitoring Board
The DSMB will review the safety, ethics and outcomes
of the study. It is independent from the sponsor and has
no competing interests. DSMB members will monitor
blinded responses of variables and SAEs for early dramatic
benefits or potential harmful effects.
A charter that will outline member responsibilities,
procedures and confidentiality will govern the DSMB.
The following are the members of the DSMB: Professor
Robert Herbert (Chair), Neuroscience Research Australia,
University of New South Wales, Sydney, Australia; Associ-
ate Professor Christopher Chen, National University of
Singapore, Singapore; and Professor Anne Forster, Bradford
Institute for Health Research, Bradford, UK.
A DSMB will also review unblinded data at regular
intervals during follow-up and will monitor neurological
and functional changes (between the two groups), as well
as dropout and event rates. These DSMB members will
use the approach developed by Sir Richard Peto for safety
monitoring and will provide reports to the InCC on
recommendations to continue or temporarily halt re-
cruitment into the study.Writing committee
Publication of the main reports derived from the study
will be in the name of the HeadPoST Collaborative Inves-
tigators. Full editorial control will reside with a writing
committee approved by the SC. Investigators have the
right to publish or present the results of the study. How-
ever, as this is a multicentre study, investigators must
agree not to publish or publicly present any interim results
of the study without the prior written permission of the
SC. Investigators must further agree to provide the SC at
least 30 days’ prior notice of any submission for publi-
cation or presentation for review, copies of abstracts
or manuscripts (including, without limitation, text and
PowerPoint presentation slides and any other texts of
translations or medial presentations) that report any
study results. Authors of publications must meet the
International Committee of Medical Journal Editors
criteria for authorship.Trial status
Ethics committees have granted permission for the study
to commence across hospitals in Australia, Brazil, Chile,
China and the United Kingdom. Patient enrolment com-
menced in February 2015. As of 2 June 2015, 435 patients
have been enrolled at 14 sites.
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Additional file 1: List of full names of the ethics committees in the
various countries and study sites that have approved the trial as of
11 May 2015.
Additional file 2: Hospital Organisation Questionnaire. Description:
Developed questionnaire to capture baseline stroke care organisational
structure of the various clinical wards within the study sites.
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